dc.creatorDe Oliveira Moreira D.
dc.creatorPereira J.A.
dc.creatorTaniguti A.P.
dc.creatorMatsumura C.Y.
dc.creatorRamos L.A.
dc.creatorAreas M.A.
dc.creatorNeto H.S.
dc.creatorMarques M.J.
dc.date2013
dc.date2015-06-25T19:18:15Z
dc.date2015-11-26T15:16:12Z
dc.date2015-06-25T19:18:15Z
dc.date2015-11-26T15:16:12Z
dc.date.accessioned2018-03-28T22:26:03Z
dc.date.available2018-03-28T22:26:03Z
dc.identifier
dc.identifierMuscle & Nerve. , v. 48, n. 6, p. 911 - 919, 2013.
dc.identifier10974598
dc.identifier
dc.identifierhttp://www.scopus.com/inward/record.url?eid=2-s2.0-84891924161&partnerID=40&md5=8216c5e6d6613d0cdddf0a3e74444655
dc.identifierhttp://www.repositorio.unicamp.br/handle/REPOSIP/89708
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/89708
dc.identifier2-s2.0-84891924161
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1259205
dc.descriptionThe purpose of this study was to determine the effects of suramin, an antifibrotic agent, on cardiac function and remodeling in mdx mice. mdx mice (8 months old) received intraperitoneal injections of suramin twice a week for 3 months. Control mdx mice (8 months old) were injected with saline. Suramin improved the electrocardiography profile with the main corrections seen in S- to R-wave ratio, PR interval, and Q amplitude, and a significant decrease in the cardiomyopathy index. Suramin decreased myocardial fibrosis, inflammation, and myonecrosis. These findings suggest that suramin may be a new adjunctive therapy to help improve cardiomyopathy in DMD. Copyright © 2013 Wiley Periodicals, Inc.
dc.description48
dc.description6
dc.description911
dc.description919
dc.languageen
dc.publisher
dc.relationMuscle & nerve
dc.rightsfechado
dc.sourceScopus
dc.titleSuramin Attenuates Dystrophin-deficient Cardiomyopathy In The Mdx Mouse Model Of Duchenne Muscular Dystrophy.
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución